RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

PHASE2CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Corneal Endothelial Cell LossOcular PainOcular InflammationCataract Surgery
Interventions
DRUG

Vehicle Ophthalmic Solution

Opthalmic suspension manufactured to mimic RTA 408 suspension

DRUG

Omaveloxolone Ophthalmic Suspension 0.5%

0.5% ophthalmic suspension of RTA 408

DRUG

Omaveloxolone Ophthalmic Suspension 1%

1% ophthalmic suspension of RTA 408

Trial Locations (15)

12603

Alterman, Modi and Wolter, Poughkeepsie

22102

See Clearly Vision Group, McLean

32204

Levenson Eye Associates, Jacksonville

33904

Argus Research, Cape Coral

45242

Cincinnati Eye Institute, Cincinnati

55082

Associated Eye Care, Stillwater

60046

JacksonEye, Lake Villa

60169

Chicago Cornea Consultants, Hoffman Estates

63090

Comprehensive Eye Care, Washington

66211

Discover Vision Centers, Leawood

78229

R & R Eye Research, San Antonio

92653

Harvard Eye Associates, Laguna Hills

93534

Hull Eye Center, Lancaster

02451

Opthalmic Consultants of Boston, Waltham

Talamo Hatch Laser Eye Consultants, Waltham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Biogen

INDUSTRY